caus
agent
dengu
fever
df
dengu
haemorrhag
fever
dhf
dengu
shock
syndrom
dss
progress
sever
clinic
manifest
dengu
infect
caus
four
singlestrand
rna
flavivirus
known
viru
transmiss
occur
infect
bite
aed
aegypti
mosquito
high
bite
frequenc
readili
interrupt
feed
behaviour
viru
replic
lymph
node
spleen
liver
mononuclear
phagocyt
cell
tissu
system
dengu
virus
encod
three
structur
protein
capsid
c
membran
envelop
e
protein
seven
nonstructur
ns
protein
america
transit
df
dhf
dss
occur
cuba
asian
genotyp
viru
introduc
popul
contrast
american
genotyp
infect
popul
iquito
peru
mild
diseas
result
differ
outcom
secondari
infect
seem
due
high
level
crossneutr
antibodi
viru
hypothes
asian
dengu
strain
success
circul
highli
dengueimmun
popul
lost
crossreact
epitop
mechan
immun
escap
import
develop
dhfdss
enhanc
viral
replic
earli
stage
infect
appar
mediat
nonneutr
antibodi
residu
earlier
dengu
infect
known
antibodydepend
enhanc
ade
earli
infect
time
interv
first
second
infect
viru
strain
host
genet
factor
involv
sever
diseas
outcom
plasma
leakag
main
pathophysiolog
featur
dhf
seem
particularli
correl
blood
concentr
cytokin
infect
cell
lysi
owe
denguespecif
lymphocyt
ultim
caus
haemorrhag
due
vasculopathi
platelet
reduct
dysfunct
prothrombincomplex
defici
even
less
clear
although
plateletactiv
factor
potenti
plateletdestroy
mechan
describ
effect
dengu
vaccin
protect
four
serotyp
longlast
avoid
antibodi
titr
drop
subneutr
level
six
live
attenu
vaccin
variou
stage
develop
two
live
attenu
vaccin
reach
phase
ii
evalu
followup
data
one
vaccin
show
protect
diseas
increas
sever
dengu
prepar
phase
iii
trial
still
consider
need
field
site
develop
epidemiolog
character
studi
popul
dengu
vaccin
could
highli
costeffect
cost
wwwnaturecomreviewsmicro
h
g
h
l
g
h
global
tb
control
report
launch
second
stop
tb
partner
forum
world
tb
day
march
contain
encourag
news
progress
made
tb
detect
treatment
past
year
howev
directorgener
lee
jongwook
caution
still
lot
work
meet
target
set
current
trend
continu
case
detect
rate
expect
way
short
target
target
import
mileston
toward
achiev
millennium
develop
goal
halv
global
burden
tb
progress
made
howev
million
individu
enrol
dot
directli
observ
treatment
short
cours
programm
worldwid
increas
million
compar
sinc
decemb
case
cholera
record
mozambiqu
least
peopl
die
emerg
mass
vaccin
campaign
way
liberia
attempt
stop
outbreak
yellow
fever
raini
season
start
april
latest
cycl
dengu
fever
indonesia
far
caus
death
led
peopl
hospit
sinc
januari
four
viral
serotyp
detect
intens
insecticid
spray
use
effort
control
mosquito
transmit
diseas
nipahlik
viru
detect
associ
outbreak
enceph
bangladesh
far
caus
death
report
lancet
provid
first
confirm
transmiss
retroviru
nonhuman
primat
human
natur
set
nathan
wolf
colleagu
investig
transmiss
simian
foami
viru
sfv
anim
human
rural
villag
cameroon
particip
studi
regularli
expos
blood
bodi
fluid
nonhuman
primat
hunt
butcher
anim
sfv
antibodi
detect
group
studi
demonstr
retrovirus
activ
transmit
human
natur
set
lent
weight
call
ban
trade
bushmeat
lancet
us
food
drug
administr
fda
judg
upheld
ban
use
fluoroquinolon
baytril
poultri
baytril
manufactur
bayer
ban
part
octob
fda
rule
outlaw
use
fluoroquinolon
poultri
feed
respons
grow
concern
intens
use
antibiot
livestock
contribut
spread
antibiot
resist
bacteria
judg
cite
seriou
question
safeti
baytril
use
poultri
bayer
plan
lodg
final
appeal
fda
commission
commission
also
back
decis
baytril
could
ban
june
per
disabilityadjust
life
year
estim
us
ref
addit
whobas
initi
vaccin
research
ivr
paediatr
dengu
vaccin
initi
pdvi
work
facilit
vaccin
develop
current
dengu
diagnost
tool
includ
antidengu
immunoglobulin
igm
detect
indic
recent
infect
use
pcr
allow
detect
dengu
viru
genom
serum
mosquito
tissu
improv
test
allow
earli
diagnosi
includ
clinic
prognosi
urgent
need
one
test
target
protein
current
develop
discoveri
drug
reduc
viral
load
dengu
patient
initi
novarti
institut
tropic
diseas
singapor
librari
million
compound
test
clone
fraction
viral
enzym
candid
lead
molecul
identifi
rapidact
compound
minim
side
effect
might
also
effect
chemoprophylact
compon
potenti
prevent
occurr
larg
outbreak
howev
success
antivir
therapi
depend
rapid
earli
diagnosi
present
method
reduc
dengu
transmiss
reduct
humanvector
contact
control
mosquito
popul
new
tool
develop
insecticidetr
curtain
improv
formul
larvicid
safe
use
drink
water
addit
implement
denguenet
global
system
standard
epidemiolog
virolog
surveil
allow
continu
updat
databas
maintain
time
control
measur
epidemiolog
research
new
strategi
polici
partnership
new
vectorcontrol
measur
new
partnership
exampl
municip
author
need
given
mosquito
habitat
manag
treatment
method
reli
involv
individu
commun
govern
manual
use
combi
approach
commun
behaviour
impact
develop
assist
programm
planner
develop
sustain
commun
action
plan
dengu
prevent
control
transgen
technolog
interupt
pathogen
transmiss
develop
aegypti
use
introduct
exogen
dna
germ
line
complet
aegypti
genom
sequenc
facilit
research
process
pipelin
vaccin
candid
look
promis
use
diseas
control
requir
care
safeti
followup
assur
sensit
sever
diseas
occur
improv
understand
molecular
mechan
pathogenesi
sever
diseas
help
overcom
threat
monitor
molecular
structur
circul
viru
expos
select
pressur
vaccineinduc
immun
import
vector
control
also
need
capac
build
essenti
sustain
deliveri
vector
control
measur
protect
highrisk
popul
respond
epidem
threat
epidem
